Navigation Links
Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
Date:1/27/2011

BLUE BELL, Pa., Jan. 27, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the closing of the sale to a single institutional investor of 21,130,400 shares of its common stock and warrants to purchase up to 10,565,200 additional shares of its common stock. The shares of common stock and warrants were sold in units consisting of one share of common stock and 0.5 of a warrant to purchase one share of common stock at a price of $1.15 per unit. The warrants have a term of five years and an exercise price of $1.40 per share. Inovio may call these warrants if the closing bid price of the common stock has been at least $2.80 over 20 trading days and certain other conditions are met.

(Logo: http://photos.prnewswire.com/prnh/20110127/LA37605LOGO)

The gross proceeds of the offering were $24.3 million and net proceeds, after deducting the placement agent's fee and estimated offering expenses payable by Inovio, were approximately $23.0 million. Roth Capital Partners acted as the sole placement agent in the offering. Brean Murray, Carret & Co. and Rodman & Renshaw, LLC served as financial advisors to the Company in the offering.

Inovio intends to use proceeds from the offering for further development of its DNA vaccine against cervical dysplasias and cancer, other preclinical and clinical studies, and general corporate purposes.

The securities described above were offered by Inovio pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission and a prospectus supplement previously filed with the SEC. Copies of the prospectus supplement and accompanying base prospectus relating to this offering may b
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 , ... Dr. Ra from Biostar , Published in ,Stem ... increase of lifespan through multiple IV administration of Adipose-derived ... and life expectancy found , Commercialization within 5 ... determined the possibility that adult mesenchymal stem cells (MSCs) ...
(Date:8/28/2015)... -- The global mHealth market ... 2020, growing at a CAGR of 47.6% from 2013 ... View Research, Inc. Monitoring services is expected to grow ... 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... of chronic diseases such as cancer, heart ailments, and ...
(Date:8/27/2015)... WASHINGTON , Aug. 27, 2015 ... Collaborative (BPC) applauds the U.S. Food and Drug ... a distinguishable name in its draft guidance issued ... of biological products proposes distinguishable names, calling for ... includes an FDA-designated suffix. This proposal reflects the ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... Dec. 5, 2011  At this week,s 46th Annual Midyear ... Health-System Pharmacists (ASHP), Cardinal Health launched BarCode360™ , ... making it easier, more timely and cost efficient to ... scanned at the patient bedside. ASHP has ...
... Pharmaceutical Co. Ltd, in which European healthcare venture capital ... as one of the Deloitte & Touche,s 50 top-performing ... the past three years. Beijing-headquartered GC-Rise, which ... revenues rising more than 270% on average per annum ...
Cached Medicine Technology:Cardinal Health Launches Innovative Barcode Administration Solution to Help Hospitals Bridge Gaps in Medication Safety 2Cardinal Health Launches Innovative Barcode Administration Solution to Help Hospitals Bridge Gaps in Medication Safety 3Women Health Expert GC-Rise Listed in Deloitte's 50 Top-performing Companies 2
(Date:8/28/2015)... ... August 28, 2015 , ... CARF International announced ... residential, counseling, day treatment and intensive family based services. , By pursuing and ... and its pursuit of excellence. As a nonprofit charity for more than 50 ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for ... is the first and only nonsurgical product approved by the Food and Drug Administration ... Quatela and Dr. William Koenig are among the premier cosmetic surgeons ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... its collaboration with coffee connoisseur and Emmy-nominated actress, Sofia Vergara, and unveil the ... revolutionary Thermal Flavor Extraction™ technology, which delivers a variety of sizes and styles ...
(Date:8/28/2015)... ... 2015 , ... The newest therapy to receive orphan drug status for the ... soon, according to educational website Surviving Mesothelioma. Click here to read their article ... mesothelioma last week from the FDA, will now head into Phase I clinical trials ...
(Date:8/28/2015)... ... 28, 2015 , ... Popular review site Top5MillionaireDatingSites.com recently published ... . According to the listings, MillionaireMatch.com bags the top spot while ... spokesperson of Top5MillionaireDatingSites.com said, “This website has been designed to assist ...
Breaking Medicine News(10 mins):Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2
... and Eliza Hall Institute have been awarded research fellowships ... research. The inaugural five-year Cory Fellowship, sponsored ... Scott and the inaugural five-year Dyson Fellowship, sponsored by ... Blewitt. At a ceremony on 25 February, Nobel ...
... and a German neurologist have recently shown that the brain ... different from the part used when a verb is learnt. ... magnetic resonance, according to an article they have published this ... activates the left fusiform gyrus, while learning verbs switches on ...
... growth, researchers say, , THURSDAY, Feb. 25 (HealthDay News) -- ... say that doses of vitamin B3 -- also known as ... stroke. , Researchers at Henry Ford Hospital found that rats ... growth and new nerve cells in their brains after being ...
... ... & Exposition (ACE10), June 20-24, in Chicago, Illinois. , ... Denver (Vocus) February 25, 2010 -- Speakers have ... (ACE10), June 20-24, in Chicago, Illinois. , ,Denis Hayes will be the highlighted speaker ...
... ... Harvey Weiner, Director, Consulting Services, CGI Federal, first contacted the Metropolitan Washington, DC ... for very personal reasons; his 2-month old daughter Melissa and 3-year old son ... the time of his children’s diagnosis, the average age of survival for a ...
... ... with Genzyme Biosurgery, is pleased to announce a new research grant program to fund ... ... 2010 -- The American Orthopaedic Society for Sports Medicine (AOSSM), in partnership ...
Cached Medicine News:Health News:Fellowship winners make cancer their focus 2Health News:Fellowship winners make cancer their focus 3Health News:Nouns and verbs are learned in different parts of the brain 2Health News:Nouns and verbs are learned in different parts of the brain 3Health News:Vitamin B3 May Help Repair Brain After a Stroke 2Health News:AWWA Announces ACE10 Speakers 2Health News:Cystic Fibrosis Foundation Awards CGI Corporation of the Year 2Health News:Cystic Fibrosis Foundation Awards CGI Corporation of the Year 3Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 2Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 3
... remarkable anti-reflux valve is enclosed ... which prevents the valve from ... in sitting or reclining positions. ... and interference free ensuring uninterrupted ...
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Intermittent catheter - SpeediCath™ is pre-hydrated and ready to use right out of the package. Just open, cath and get on with your life....
Medicine Products: